Asenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

International Journal of Clinical Practice

Volumn 63, Issue 12, 2009, Pages 1762-1784

  Citrome, L ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ASENAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; OLANZAPINE; PLACEBO; RISPERIDONE; SEROTONIN 2A RECEPTOR;

AKATHISIA; AMINOTRANSFERASE BLOOD LEVEL; BIPOLAR DISORDER; BIPOLAR I DISORDER; CLINICAL TRIAL; DELUSION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FOOD; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPESTHESIA; MAJOR DEPRESSION; MANIA; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RECEPTOR AFFINITY; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; WEIGHT GAIN;

ADMINISTRATION, SUBLINGUAL; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CYTOCHROME P-450 ENZYME SYSTEM; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 70449408797     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02228.x     Document Type: Review

References (24)

1. United States Food and Drug Administration. FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder. Press release, 14 August 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm177401.htm (accessed August 2009).
2. Schering-Plough Corporation. Saphris (Asenapine) Sublingual Tablets US Prescribing Information. Revised August 2009. http://www.spfiles.com/ pisaphrisv1.pdf (accessed August 2009).
3. Stevenson R, Wolde HT. Update 4 - Akzo, Pfizer Scrap Asenapine Joint Development. 28 November 2006. http://www.reuters.com/article/companyNewsAndPR/ idUSL286087420061128 (accessed August 2009).
4. Costall B, Domeney AM, Kelly ME, Naylor RJ, Tomkins DM. Actions of ORG 5222 as a novel psychotropic agent. Pharmacol Biochem Behav 1990 35 : 607 615.
5. United States Food and Drug Administration. Saphris (Asenapine) Sublingual Tablets. Briefing Book. 30 July 2009. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ PsychopharmacologicDrugsAdvisoryCommittee/UCM173877.pdf (accessed August 2009).
6. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007 68 : 1492 1500.
7. Friberg LE, de Greef R, Kerbusch T, Karlsson MO. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 2009 86 : 84 91.
8. Alphs L, Panagides J, Lancaster S. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale. Psychopharmacol Bull 2007 40 : 41 53.
9. Andrée B, Halldin C, Vrijmoed-de Vries M, Farde L. Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology (Berl) 1997 131 : 339 345.
10. Weber J, McCormack PL. Asenapine. CNS Drugs 2009 23 : 781 792.
11. Schering-Plough Research Institute. Saphris (Asenapine) Sublingual Tablets. Briefing Document (Background Package). 30 July 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173876.pdf (accessed August 2009).
12. Citrome L. Show me the evidence: using number needed to treat. South Med J 2007 100 : 881 884.
13. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 2008 117 : 412 419.
14. Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009 4 : 229 237.
15. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006 59 : 990 996.
16. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004 9 (Suppl. 11 6 14.
17. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009 23 : 65 73.
18. Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003 28 : 519 526.
19. Kaufmann H, Bhattacharya K. Diagnosis and treatment of neutrally mediated syncope. Neurologist 2002 8 : 175 185.
20. United States Food and Drug Administration. NDA Approval Letter. 13 August 2009. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2009/ 022117s000ltr.pdf (accessed August 2009).
21. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009 373 : 31 41.
22. Leucht S, Komossa K, Rummel-Kluge C et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009 166 : 152 163.
23. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009 14 : 429 447.
24. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009 10 : 1917 1928.